Pharmacologic or genetic ablation of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents.
about
Role of dichloroacetate in the treatment of genetic mitochondrial diseasesPhysiologically based pharmacokinetic modeling of dibromoacetic acid in F344 rats.Mitochondrion as a novel site of dichloroacetate biotransformation by glutathione transferase zeta 1.The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?The heme precursor delta-aminolevulinate blocks peripheral myelin formation.Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in childrenKey issues in the modes of action and effects of trichloroethylene metabolites for liver and kidney tumorigenesisChloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans.Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity.Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate.Glutathione transferase zeta: discovery, polymorphic variants, catalysis, inactivation, and properties of Gstz1-/- mice.A Mechanism-Based Pharmacokinetic Enzyme Turnover Model for Dichloroacetic Acid Autoinhibition in Rats.Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1.Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics and oral bioavailability in human volunteers: a stable isotope study.
P2860
Q24630740-8B156966-95B8-4E09-B0DA-B19CE4A336C6Q33759163-9FACA1C9-8752-4AA7-9AAB-CECCEBBE5C08Q34458616-0B573C5A-A4BF-4990-977B-71507C3FAC9AQ34580854-C181C53B-C231-4507-9B09-06F4FF9A4CABQ34594889-D6BE616E-0008-4E30-9561-A80397F3A086Q34771992-D1D9A71D-28CA-475D-8A52-01B796689A70Q35039264-2B345091-153B-4F30-82A7-31459DC68FD6Q35684236-EDA69497-A340-45A3-96AE-D12CCEB36624Q37036347-C9933AF5-7981-4F79-B077-E790AECE0242Q37206708-194DDD5E-1CEF-4F36-893B-ED08D87BE4CAQ37837879-0FC1D269-CE90-4A90-8AAD-0DD447CFBD92Q38978157-0FC280C9-47BD-402F-A64B-6F8833FA539EQ38988403-FB9059BB-C25E-4F96-974F-8432DEC79EADQ51227133-14A78253-B0C4-4539-9ACF-C1FC0EFA34CE
P2860
Pharmacologic or genetic ablation of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Pharmacologic or genetic ablat ...... rosine catabolites in rodents.
@en
Pharmacologic or genetic ablat ...... rosine catabolites in rodents.
@nl
type
label
Pharmacologic or genetic ablat ...... rosine catabolites in rodents.
@en
Pharmacologic or genetic ablat ...... rosine catabolites in rodents.
@nl
prefLabel
Pharmacologic or genetic ablat ...... rosine catabolites in rodents.
@en
Pharmacologic or genetic ablat ...... rosine catabolites in rodents.
@nl
P2093
P1476
Pharmacologic or genetic ablat ...... rosine catabolites in rodents.
@en
P2093
Albert L Shroads
Chandramohan V Ammini
George N Henderson
Jang Cheung
Jose Fernandez-Canon
Peter W Stacpoole
Rachel Cornett
P304
P356
10.1016/J.BCP.2003.07.002
P407
P577
2003-11-01T00:00:00Z